Home / Knowledge Centre /

Carbon-14 Bioconjugation: Peptides and Antibody Drug Conjugates

Almac explains how the synergy between their peptide and protein technology and radiolabeling groups can enable the manufacture of carbon-14 labeled peptides and antibody-drug conjugates (ADCs) to meet customer requirements.

View Resource

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies